Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$0.12 - $0.5 $363 - $1,513
3,027 Added 95.97%
6,181 $0
Q3 2023

Oct 30, 2023

BUY
$0.12 - $0.5 $363 - $1,513
3,027 Added 95.97%
6,181 $1,000
Q2 2023

May 21, 2024

SELL
$0.43 - $0.65 $44 - $66
-103 Reduced 3.16%
3,154 $1,000
Q2 2023

Jul 27, 2023

SELL
$0.43 - $0.65 $44 - $66
-103 Reduced 3.16%
3,154 $2,000
Q1 2023

May 21, 2024

BUY
$0.46 - $0.81 $374 - $660
815 Added 33.37%
3,257 $2,000
Q1 2023

Apr 27, 2023

BUY
$0.46 - $0.81 $374 - $660
815 Added 33.37%
3,257 $2,000
Q4 2022

May 21, 2024

BUY
$0.5 - $261.0 $1,221 - $637,362
2,442 New
2,442 $1,000
Q4 2022

Jan 31, 2023

BUY
$0.5 - $261.0 $209 - $109,098
418 Added 20.65%
2,442 $2,000
Q3 2022

Oct 21, 2022

BUY
$1.04 - $322.5 $2,104 - $652,740
2,024 New
2,024 $3,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $458M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.